More than 50 potential therapies are moving through clinical development as pharmaceutical companies search for new ways to improve pain management after surgery
New York, New York, 13 August 2026 – The race to develop better treatments for pain after surgery is gaining momentum, with more than 45 pharmaceutical companies actively working on new medicines for the market. According to DelveInsight’s Postoperative Pain Management Pipeline Insight 2026 report, the research landscape currently includes more than 52 drug candidates at different stages of development.
Postoperative pain is a common concern following surgical procedures. While existing pain medicines can help patients manage discomfort, there is continued demand for treatments that can provide effective pain relief while addressing limitations associated with current options. This has encouraged pharmaceutical companies to explore new drug formulations, mechanisms of action, and treatment approaches.
The pipeline includes several companies working to strengthen the future treatment landscape. Among them are Ensysce Biosciences, Xgene Pharmaceutical Group, Jiangsu Hengrui Pharmaceuticals, Allay Therapeutics, Bausch and Lomb, Latigo Biotherapeutics, and other drug developers. Their research programs include medicines designed for different types of postoperative pain and are being evaluated through various stages of clinical development.
Several drug candidates are already attracting attention as development progresses. Therapies including PF614, XG005, HRS 2129, ATX101, BL1332, HL 1186 and others are currently being studied. More than 12 of the pipeline candidates are in mid- or late-stage development, suggesting that several potential treatments are moving closer to the point where they could seek regulatory review and eventual market entry.
Clinical trials are an important part of this process. Before a new medicine can reach patients, developers must study how well it works and evaluate its safety. These trials can take several years and involve different phases, with each stage providing more information about the treatment. Late-stage development is particularly important because it can bring a drug closer to regulatory submission.
The growing number of therapies under development also reflects the competitive nature of the pain management market. Companies are exploring a variety of approaches rather than relying on a single type of medicine. Some programs focus on improving the duration of pain relief, while others are investigating different ways of targeting the body’s pain pathways.
DelveInsight’s report also examines the wider business and development activity surrounding these treatments. This includes clinical trial progress, collaborations, licensing arrangements, regulatory pathways and other activities that can influence how quickly a potential medicine advances. The report covers therapies from early research through later stages of development, providing a broader view of how the postoperative pain treatment pipeline is evolving.
For the pharmaceutical industry, a strong pipeline creates both opportunities and challenges. Developing a successful pain treatment requires significant investment, detailed clinical research, and the ability to demonstrate value in a competitive healthcare market. Not every drug in development will reach the market, as some candidates may face clinical, safety, or regulatory challenges along the way.
Still, the current level of research indicates continued interest in improving how pain is managed after surgery. As more clinical trial data becomes available, the industry will gain a clearer picture of which therapies have the strongest potential to advance.
With more than 50 drug candidates under development and dozens of companies involved, postoperative pain management remains an active area of pharmaceutical innovation. The next few years could bring important changes as mid- and late-stage therapies progress through clinical trials and developers work toward potential market entry.
